The adverse effects of antiepileptic drugs in children

Expert Opinion on Drug Safety

Volumn 6, Issue 3, 2007, Pages 251-265

  Kothare, Sanjeev V ^a   Kaleyias, Joseph ^a  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

Author keywords

Adverse effects; Antiepileptic drugs; Children; Epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; CALCIUM; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOLIC ACID; FOLIC ACID ANTAGONIST; GABAPENTIN; LAMOTRIGINE; LIPID; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; VITAMIN D; VITAMIN K GROUP; ZONISAMIDE;

ABSENCE; ACADEMIC ACHIEVEMENT; ACUTE PSYCHOSIS; AGE DISTRIBUTION; AGRANULOCYTOSIS; ALOPECIA; ANOREXIA; ANTICONVULSANT ACTIVITY; ANTISOCIAL BEHAVIOR; APLASTIC ANEMIA; AROUSAL; ASTHENIA; ATAXIA; ATRIOVENTRICULAR BLOCK; AUDITORY HALLUCINATION; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BIRTH DEFECT; BLOOD DISEASE; BLOOD DYSCRASIA; BODY WEIGHT; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE TURNOVER; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONCENTRATION LOSS; CONGENITAL MALFORMATION; CYTOPENIA; DEPRESSION; DEVELOPMENTAL DISORDER; DIPLOPIA; DISEASE PREDISPOSITION; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPAREUNIA; ENDOCRINE FUNCTION; ENZYME INDUCTION; EPILEPSY; EPILEPTIC STATE; EXCITABILITY; FATIGUE; FIRST TRIMESTER PREGNANCY; FOCAL EPILEPSY; FOLIC ACID BLOOD LEVEL; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL TOXICITY; GINGIVA HYPERTROPHY; GRAND MAL SEIZURE; HAND TREMOR; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HEMOGLOBINOPATHY; HEMOLYTIC ANEMIA; HIGH RISK POPULATION; HIRSUTISM; HORMONE ACTION; HUMAN; HYPERACTIVITY; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERTHERMIA; HYPONATREMIA; INFANTILE SPASM; INSOMNIA; INTELLIGENCE QUOTIENT; IRRITABILITY; KIDNEY FAILURE; LANGUAGE DISABILITY; LETHARGY; LEUKOPENIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER DISEASE; LIVER FAILURE; LOW DRUG DOSE; MEMORY DISORDER; MENSTRUATION DISORDER; MENTAL CONCENTRATION; META ANALYSIS; MOOD CHANGE; MOTOR DYSFUNCTION; MULTIPLE ORGAN FAILURE; MYOCLONUS; MYOCLONUS SEIZURE; NAUSEA; NEPHROLITHIASIS; NEURAL TUBE DEFECT; NEUROLOGIC DISEASE; NEUTROPENIA; NYSTAGMUS; OBESITY; OBSESSIVE COMPULSIVE DISORDER; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; OVARY POLYCYSTIC DISEASE; PANCREAS INSUFFICIENCY; PANCYTOPENIA; PARESTHESIA; PHOTOPHOBIA; POLYPHARMACY; PRENATAL DRUG EXPOSURE; PSEUDOLYMPHOMA; PSYCHOMOTOR DISORDER; PSYCHOSIS; REM SLEEP; REPRODUCTIVE HEALTH; REVIEW; RISK REDUCTION; SCREAMING SYNDROME; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP PATTERN; SLOW WAVE SLEEP; SOMNOLENCE; SPEECH DISORDER; STEVENS JOHNSON SYNDROME; STOMACH DISEASE; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENESIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; TIC; TREMOR; UROLITHIASIS; VAGINAL DRYNESS; VAGINISM; VISUAL FIELD DEFECT; VITAMIN BLOOD LEVEL; VOMITING; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; BLOOD; BLOOD CELL; DRUG EFFECT; FEMALE; FETUS; PREGNANCY; REPRODUCTION; SLEEP;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; BLOOD CELLS; BODY WEIGHT; BONE DENSITY; CHILD; COGNITION; FEMALE; FETUS; HUMANS; LIPIDS; PREGNANCY; REPRODUCTION; SLEEP;

EID: 34248597538     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.3.251     Document Type: Review

References (133)

1. MATTSON RH, CRAMER JA, COLLINS JF et al.: Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized ionic-clonic seizures. N. Engl. J. Med. (1985) 313(3):145-151.
2. COLLABORATIVE GROUP FOR EPIDEMIOLOGY OF EPILEPSY. Adverse reaction to antiepileptic drugs: a multi-centre survey of clinical practice. Epilepsia (1986) 27(4):323-330.
3. BAZIL CW: Antiepileptic drugs in the 21st century. CNS Spectr. (2001) 6(9):756-765.
4. ROGVI-HANSEN B, GRAM L: Adverse effects of established and new antiepileptic drugs: an attempted comparison. Pharmacol. Ther. (1995) 68(3):425-434.
5. MATTSON RH: Efficacy and adverse effects of established and new antiepileptic drugs. Epilepsia (1995) 36(Suppl. 2):S13-S26.
6. GREENWOOD RS: Adverse effects of antiepileptic drugs. Epilepsia (2000) 41(Suppl. 2):S42-S52.
7. ANDERSON GD: Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia (2002) 43(Suppl. 3):S53-S59.
8. NORDLI DR Jr: The management of epilepsy in children: cognitive and behavioral side effects. Rev. Neurol. Dis. (2004) 1(Suppl. 1):S4-S9.
9. LORING DW, MEADOR KJ: Cognitive side effects of antiepileptic drugs in children. Neurology (2004) 62(6):872-877.
10. THE FOOD AND DRUG ADMINISTRATION: Record and reports concerning adverse drug experiences on marketed prescription drugs. Federal Register, Washington, DC, USA, October 7 (1997).
11. BROWN EG, WOOD L, WOOD S: The medical dictionary for regulatory activities (MedDRA). Drug Saf. (1999) 20(2):109-117.
12. CRAMER JA, FISHER R, BEN MENACHEN E, FRENCH J, MATTSON RH: New antiepileptic drugs: comparison of key clinical trials. Epilepsia (1999) 40(5):590-600.
13. PERUCCA E, MEADOR KJ: Adverse Effects of antiepileptic drugs. Acta Neurol. Scand. Suppl. (2005) 181:30-35.
14. BERKOVIC SF: Aggravation of generalized cpilepsies. Epilepsia (1998) 39(Suppl. 3):S11-S14.
15. PERUCCA E, GRAM L, AVANZINI G, DULAC O: Antiepileptic drugs as a cause of worsening seizures. Epilepsia (1998) 39(1):5-17.
16. GUERRINI R, DRAVET C, GENTON P, BELMONTE A, KAMINKSA A, DULAC O: Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia (1998) 39(5):508-512.
17. ELGER CE, BAUER J, SCHERRMANN J, WIDMAN G: Aggravation of focal epileptic seizures by antiepileptic drugs. Epilepsia (1998) 39(Suppl. 3):S15-S18.
18. GUERRINI R, BELMONTE A, GENTON P: Antiepileptic drug induced worsening of seizures in children. Eplepsia (1998) 39(Suppl. 3):S2-S10.
19. FITZEK S, HEGEMANN S, SAUNER D, BONSCH D, FITZEK C: Drug-induced nonconvulsive status epilepticus with low dose of tiagabine. Epileptic Disord. (2001) 3(3):147-150,
20. JETTE N, CAPPELL J, VAN PASSEL L, AKMAN CI: Tiagabine-induced nonconvulsive status epilepticus in an adolescent without epilepsy. Neurology (2006) 67(8):1514-1515.
21. PELLOCK JM: Treatment of seizures and epilepsy in children and adolescents. Neurology (1998) 51(Suppl. 4):S8-S14.
22. SCHLIENGER RG, SHAPIRO LE, SHEAR NH: Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia (1998) 39(Suppl. 7):S22-S26.
23. BROWN WM, AIKEN SP: Felbamate: clinical and molecular aspects of a unique antiepileptic drug. Crit. Rev. Neurobiol. (1998) 12(3):205-222.
24. LEEDER JS: Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia (1998) 39(Suppl. 7):S8-S16.
25. HOLMES LB: The teratogenicity of anticonvulsant drugs: a progress report. J. Med. Gen. (2002) 39(4):245-247.
26. HOLMES LB, HARVEY EA, COULL BA et al.: The teratogenicity of anticonvulsant drugs. N. Engl. J. Med. (2001) 344(15):1132-1138.
27. DOLK H, MCELHATTON P: Assessing epidemiological evidence for the teratogenic effects of anticonvulsant medications. J. Med. Genet. (2002) 39(4):243-244.
28. KAPLAN PW: Reproductive health effects and teratogenicity of antiepileptic drugs. Neurology (2004) 63(Suppl. 4):S13-S23.
29. DELLAPORTAS DI, SHORVON SD, GALBRAITH AW et al.: Chronic toxicity in epileptic patients receiving single-drug treatment. Br. Med. J. (1982) 285:409-410.
30. SMITHELLS RW, SHEPPARD S, SCHORAH CJ: Vitamin deficiencies and neural tube defects. Arch. Dis. Child (1976) 51:944-950.
31. DANSKY LV, ANDERMANN E, ROSENBLATT D, SHERWIN AL, ANDERMANN F: Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Ann. Neurol. (1987) 21(2):176-182.
32. HALL J, SOLEHDIN F: Folic acid for the prevention of congenital anomalies. Eur J. Pediatr. (1998) 157(6):445-450.
33. HERNANDEZ-DIAZ S, WERLER MM, WALKER AM, MITCHELL AA: Folic acid antagonists during pregnancy and the risk of birth defects. N. Engl. J. Med. (2000) 343(22):1608-1614.
34. WYSZYNSKI DF, NAMBISAN M, SURVE T et al.: Increased rate of malformations in offipring exposed to valproare during pregnancy. Neurology (2005) 64(6):961-965.
35. NAMBISAN M, WYSZYNSKI DF, HOLMES LB: No evidence of a protective effect due to periconceptional folic acid (PCFA) intake on risk of congenital anomalies in the offspring of mothers exposed to antiepileptic drugs (AEDs). Birth Defects Res. (2003) 67:5.
36. BUCHLER BA, RAO V, FINNELL RH: Biochemical and molecular teratology of fetal hydantoin syndrome. Pediatr. Neurogenetics (1994) 12(4):741-748.
37. MOTAMEDI GK, MEADOR KJ: Antiepileptic drugs and neurodevelopment. Curr. Neurol. Neurosci. Rep. (2006) 6(4):341-346.
38. TOMSON T, BATTINO D: Teratogenicity of the antiepileptic drugs: state of the art. Curr. Opin. Neurol. (2005) 18(2):135-140.
39. ALSDORF R, WYSZYNSKI DF: Teratogenicity of sodium valproate. Expert. Opin. Drug Saf. (2005) 4(2):345-353.
40. OMTZIGT JG, LOS FJ, GROBBEE DE et al.: The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology (1992) 42(4 Suppl. 5):S119-S125.
41. HOLMES LB, WYSZYNSKI DF, LIEBERMAN E: The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch. Neurol. (2004) 61(5):673-678.
42. SABRY M, FARAG T. Hand anomalies in fetal-hydantoin syndrome: from nail/ phalangeal hypoplasia to unilateral acheiria. Am. J. Med. Genet. (1996) 62(4):410-412.
43. HERNANDEZ-DIAZ S, WERLER MM, WALKER AM, MITCHELL AA: Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am. J. Epidemiol. (2001) 153(10):961-968.
44. MATALON S, SCHECHTMAN S, GOLDWEIG G, ORMOY A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod. Toxicol. (2002) 16(1):9-17.
45. PALMIERI C, CANGER R: Teratogenic potential of the newer antiepileptic drugs: what is known and how should this influence prescribing? CNS Drugs (2002) 16(11):28-32.
46. BEGHI E, ANNEGERS JF; COLLABORATIVE GROUP FOR THE PREGNANCY REGISTRIES IN EPILEPSY. Pregnancy registries in epilepsy. Epilepsia (2001) 42(11):1422-1425.
47. VAJDA Fj, O'BRIEN TJ, HITCHOCK A et al.: Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J. Clin. Neurosci. (2004) 11:854-858.
48. PERRUCA E: Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol. (2005) 4:781-786.
49. CUNNINGTON M, TENNIS P; THE INTERNATIONAL LAMOTRIGINE PREGNANCY REGISTRY ADVISORY COMMITTEE: Lamotrigine and the risk of malformations in pregnancy. Neurology (2005) 64(6):955-960.
50. MONTOURIS G: Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr. Med. Res. Opin. (2005) 21(5):693-701.
51. HUNT S, GRAIG J, RUSSELL A et al.: Levetiracetam in pregnancy: preliminary experience from the UK epilepsy and Pregnancy Register. Neurology (2006) 67(10):1876-1879.
52. TEN BERG K, SAMREN EB, VANOPPEN AC, ENGELSMAN M, LINDHOUT D: Levetiracetam use and pregnancy outcome. Reprod. Toxicol. (2005) 20(1):175-178.
53. MEADOR KJ: Neurodevelopmental effects of antiepileptic drugs. Curr. Neurol. Neurosci. Rep. (2002) 2(4):372-378.
54. ADAB N, JACOBYA, SMITH D, CHADWIC D: Additional educational needs in children born to mothers with epilepsy. J. Neurol. Neurosurg. Psychiatr. (2001) 70(1):15-21.
55. ADAB N, KINI U, VINTEN J et al.: The longer term outcome of children born to mothers with epilepsy. J. Neurol. Neurosurg. Psychiatr. (2004) 75(11):1575-1583.
56. ADAB N, TUDUR SC, VINTEN J, WILLIAMSON P, WINTERBOTTOM J: Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database Syst. Rev. (2004) 3:CD004848.
57. THORP JA, O'CONNOR M, BELDEN B, ETZENHOUSER J, HOFFMAN EL, JONES PG: Effects of phenobarbital and multiple-dose corticosteroids on developmental outcome at age 7 years. Obstet. Gynecol. (2003) 101(2):362-373.
58. REINISCH JM, SANDERS SA, MORTENSEN EL, RUBIN DB: In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA (1995) 274(19):1518-1525.
59. MEADOR KJ, BAKER GA, FINNELL RH et al.; for the NEAD STUDY GROUP: In utero antiepileptic drug exposure: fetal deaths and malformations. Neurology (2006) 67(3):407-412.
60. TOMSON T. Gender aspects of pharmacokinetics; of new and old AEDs. Pregnancy and breast-feeding. Ther. Drug Monit. (2005) 27(6):718-721.
61. YERBY MS, FRIEL PN, MCCORMICK K: Antiepileptic drug disposition during pregnancy and lactation. Neurology (1992) 42(Suppl. 5):S12-S16.
62. JOHANNESSEN SI, TOMSON T: Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin. Pharamcokinet. (2006) 45(11):1061-1075.
63. PENNELL PB, NEWPORT DJ, STOWE ZN et al.: The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology (2004) 62(2):292-295.
64. SANKAR R, HOLMES GL: Mechanisms of action for the commonly used antiepileptic drugs: relevance to andepileptic drug-associated neurobehavioral adverse effects. J. Child Neurol. (2004) 19(Suppl. 1):S6-S14.
65. MATTSON RH: Cognitive, affective, and behavioral side effects in adults secondary to antiepileptic drug use. Rev. Neurol. Dis. (2004) 1(Suppl. 1):S10-S17.
66. NO AUTHORS LISTED: Behavioral and cognitive effects of anticonvulsant therapy. American Academy of Pediatrics Committee on Drugs. Pediatrics (1995) 96(3 Pt 1):538-540.
67. HIRTZ D, BERG A, BETTIS D et al.: Practice parameter: treatment of the child with a first unprovoked seizure: report on the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology (2003) 60(2):166-175.
68. HESSEN E, LOSSIUS MI, REINVANG I, GJERSTAD L: Influence of major antiepileptic drugs in attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. Epilepsia (2006) 47(12):2038-2045.
69. SILLANPAA M, JALAVA M, KALEVA O, SHINNAR S: Long-term prognosis of seizures with onset in childhood. N. Engl. J. Med. (1998) 338(26):1715-1722.
70. SULZBACHER S, FARWELL JR, TEMKIN N, LU AS, HIRTZ DG: Late cognitive effects of early treatment with phenobarbital. Clin. Pediatr (1999) 38(7):387-394.
71. SEIDEL WT, MITCHELL WG: Cognitive and behavioral effects of carbamazepine in children: data from benign rolandic epilepsy. J. Child Neurol. (1999) 14(11):716-723.
72. FORSYTHE I, BUTLER R, BERG I, MCGUIRE R: Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin, and sodium valproate. Dev. Med. Child Neurol. (1991) 33(6):524-534.
73. VINING EP, MELLITIS ED, DORSEN MM et al.: Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics (1987) 80(2):165-174.
74. ELTERMAN RD, GLAUSER TA, WYLLIE E, REIFE R, WU SC, PLEDGER G: A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology (1999) 52(7):1138-1344.
75. FRITZ N, GLOGAU S, HOFFMANN J, RADEMACHER M, ELGER CE, HELMSTAEDTER C: Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav. (2005) 6(3):373-381.
76. TALLIAN KB, NAHATA MC, LO W, TSAO CY. Gabapentin associated aggressive behaviour in pediatric patients with seizures. Epilepsia (1996) 37(5):501-502.
77. ERIKSSON AS, NERGARDH A, HOPPU K: The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double blind, cross-over study. Epilepsia (1998) 39(5):495-501.
78. LAGAE L: Cognitive side effects of anti-epileptic drugs. The relevance in childhood epilepsy. Seizure (2006) 15(4):235-241.
79. WHELESS JW. NG YT. Levetiracetam in refractory pediatric epilepsy. J. Child Neurol. (2002) 17(6):413-415.
80. KOSSOFF EH, BERGEY GK, FREEMAN JM, VINING EP: Levetiracetam psychosis in children with pilepsy. Epilepsia (2001) 42(12):1611-1613.
81. HIRAI K, KIMIYA S, TABATA K, SEKI T, JOZAKI K, KUMAGAI N: Selective mutism and obsessive compulsive disorders associated with zonisamide. Seizure (2002) 11(7):468-470.
82. ZAMPONI N, CARDINALI C: Open comparative long-term study of vigabatrin versus carbamazepine in newly diagnosed partial seizures in children. Arch. Neurol. (1999) 56(5):605-607.
83. HAHN TJ, HENDIN BA, SCHARP CR, HADDAD JG Jr: Effect of chronic anticonvulsant therapy on serum 25-hydroxycalceferol levels in adults. N. Engl. J. Med. (1972) 287(18):900-904.
84. ALI II, SCHUH L, BARKLEY GL, GATES JR, Antiepileptic drugs and reduced bone mineral density. Epilepsy Behav. (2004) 5(3):296-300.
85. PACK AM, MORRELL MJ: Adverse effects of antiepileptic drugs on bone structure. CNS Drugs (2001) 15(8):633-642.
86. PACK AM: The association between antiepileptic drugs and bone disease. Epilepsy Curr. (2003) 3(3):91-95.
87. TELCI A, CAKATAY U, KURT BB et al.: Changes in bone turnover and deoxypyridinoline levels in epileptic patients. Clin. Chem. Lab. Med. (2000) 38(1):47-50.
88. MOSEKIDLE L, MELSEN F: Dynamic differences in trabecular bone remodeling between patients after jejuno-ileal bypass for obesity and epileptic patients receiving anticonvulsant drug therapy. Metal Bone Dis. Relat. Res. (1980) 12:184-186.
89. MAZESS RB, BARDEN HS: Measurement of bone by dual-photon absorptiometry (DPA) and dual-energy X-ray absorptiometry (DEXA). Ann. Chir. Gynaecol. (1988) 77(5-6):197-203.
90. PLUSKIEWICZ W. NOWAKOWSKA J: Bone status after long-term anticonvulsant therapy in epileptic patients: evaluation using quantitative ultrasound of calcaneus and phalanges. Ultrasound Med. Biol. (1997) 23(4):553-558.
91. CHUNG S, AHN C: Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev. (1994) 16(5):382-385.
92. STEPHEN LJ, MCLELLAN AR, HARRISON JH et al.: Bone density and antiepileptic drugs: a case controlled study. Seizure (1999) 8(6):339-342.
93. SHETH RD, WESOLOWSKI CA, JACOB JC et al.: Effect of carbamazepine and valproate on bone mineral density. J. Pediatr. (1995) 127(2):256-262.
94. NICOLAIDOU P, GEORGOULI H, KOTSALIS H et al.: Effects of anticonvulsant therapy on vitamin D status in children: a prospective monitoring study. J. Child Neurol. (2006) 21(3):205-209.
95. MINTZER S, BOPPANA P, TOGURI J, DESANTIS A: Vitamin D levels bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia (2006) 47(3):510-515.
96. KUMANDAS S, KOKLU E, GUMUS H et al.: Effect of carbamazepine and valproic acid on bone mineral density, IGF-I and IGFBP-3. J. Pediatr. Endocrinol. Metab. (2006) 19(4):529-534.
97. SHETH R, WESPLEWSKI CA, JACOB JC et al.: Effect of carbamazepine and valproate on bone mineral density. J. Pediatr. (1995) 127:256-262.
98. VESTERGAARD P. TIGARAN S, REJNMARK L, TIGARAN C, DAM M, MOSEKILDE L: Fracture risk is increased in epilepsy. Acta Neurol. Scand. (1999) 99(5):269-275.
99. MIKATI MA, DIB L, YAMOUT B, SAWAYA R, RAHI AC, FULEIHAN GEL-H: Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology (2006) 12(11):2005-2014.
100. VERROTTI A, BASCIANI F, DOMIZIO S, SABATINO G, MORGESE G, CHIARELLI F: Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatr. Neurol. (1998) 19(5):364-367.
101. SONMEZ FM, DEMIR E, OREM A et al.: Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J. Child Neurol. (2006) 21(1):70-74.
102. CASTRO-GAGO M, NOVO-RODRIGUEZ MI, BLANCO-BARCA MO et al.: Evolution of serum lipids and lipoprotein (a) levels in epileptic children treated with carbamazepine, valproic acid, and phenobarbital. J. Child Neurol. (2006) 21(1):48-53.
103. HOBBS HH, WHITE AL: Lipoprotein (a): intrigues and insights. Curr. Opin. Lipidol. (1999) 10(3):225-236.
104. LEIBOWITZ SF: Neurochemical-neuroendocrine systems in the brain controlling macronutrient intake and metabolism. Trends Neurosci. (1992) 15(12):491-497.
105. National Center for Health Statistics. Healthy People 2000 Review 1998-1999, Hyattsville, Maryland: Public Health Service, 1999. DHHS publication (PHS) 99-1256.
106. NOVAK GP, MAYTAL J, ALSHANSKY A, EVIATAR L, SY-KHO R, SIDDIQUE Q: Risk of excess ive weight gain in epileptic children created with valproate. J. Child Neurol. (1999) 14(8):490-495.
107. BERGEN DC, RISTANOVIC RK, WAICOSKY K, KANNER A, HOEPPNER TJ: Weight loss in patients taking felbamare. Clin. Neuropharmacol. (1995) 18(1):23-27.
108. SHORVON SD: Safety of topiramate: adverse events and relationships to dosing. Epilepsia (1996) 37(Suppl. 2):S18-S22.
109. FRANKS S: Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome in defense of the Rotterdam criteria. J. Clin. Endocrinol. Metab. (2006) 91(3):786-789.
110. ISOJARVI JI, LAATIKAINEN TJ, PAKARINEN AJ, JUNTUNEN KT, MYLLYLA VV: Polycystic ovaries and hyperadrogenism in women taking valproare for epilepsy. N. Engl. J. Med. (1993) 329(19):1383-1388.
111. ISOJARVI JI, TAUBOLL E, PAKARINEN AJ et al.: Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am. J. Med. (2001) 111(4):290-296.
112. LEUF G, ABRAHAM I, HASLINGER M et al.: Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J. Neurol. (2002) 249(7):835-841.
113. RATTYA J, PAKARINEN AJ, KNIP M, REPO-OUTAKOSKI M, MILLYLA VV, ISOJARVI JI: Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology (2001) 57(3):440-444.
114. ISOJARVI JI, RATTYA J, MYLLYLA VV et al.: Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann. Neurol. (1998) 43(4):446-451.
115. O'BRIEN MD, GUILLEBAUD J: Contraception for women with epilepsy. Epilepsia (2006) 47(9):1419-1422.
116. SAMMARITANO M, SHERWIN A: Effect of anticonvulsants on sleep. Neurology (2000) 54(Suppl. 1):S16-S24.
117. LEGROS B, BAZIL CW: Effect of antiepileptic drugs on sleep architecture: a pilot study. Sleep Med. (2003) 4(1):51-55.
118. FOLDVARY-SCHAEFER N: Sleep complaints and epilepsy: the role of seizures, antiepileptic drugs and sleep disorders. J. Clin. Neurophysiol. (2002) 19(6):514-521.
119. CORTSESI F, GIANNOTI F, OTTAVIANO S: Sleep problems and daytime behavior in childhood idiopathic epilepsy. Epilepsia (1999) 40(11):1557-1565.
120. PALM L, ANDERSON H, ELMQVIST D, BLENNOW G: Daytime sleep tendency before and after discontinuation of antiepileptic drugs on preadolescent children with epilepsy. Epilepsia (1992) 33(4):687-689.
121. MALOW BA, LEVY K, MATUREN K, BOWES R: Obstructive sleep apnea is common in medically refractory epilepsy patients. Neurology (2000) 55(7):1002-1007.
122. BLACKBURN SC, OLLART AD, GARCIA RODRIQUEZ LA et al.: Antiepileptic drugs and blood dyscrasias: a cohort study. Pharmacotherapy (1998) 18(6):1277-1283.
123. ASADU-POOYA AA, GHETMIRI E: Folic acid supplementation reduces the development of some blood cell abnormalities in children receiving carbamazepine. Epilepsy Behav. (2006) 8:228-231.
124. ONAT F, OZKARA C: Adverse effects of the new antiepileptic drugs. Drugs Today (Barc) (2004) 40(4):325-342.
125. SANDER JM: New drugs for epilepsy. Curr. Opin. Neurol. (1998) 11(2):141-148.
126. HANDOKO KB, SOUVEREIN PC, VAN STAA TP et al.: Risk for aplastic anemia in patients using antiepileptic drugs. Epilepsia (2006) 47(7):1232-1236.
127. HARDEN CL: Therapeutic safety monitoring: what to look for and when to took for it. Epilepsia (2000) 41(Suppl. 8):S37-S44.
128. HOLLAND KD: Efficacy, pharmacology and adverse effects of antiepileptic drugs. Neurol. Clin. (2001) 90(2):313-345.
129. SIDDIQUI A, KERB R, WEALE ME et al.: Association of multi-drug resistance with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. (2003) 348(15):1480-1482.
130. SEO T, ISHITSU T, UEDA N et al.: ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics (2006) 7(4):551-561.
131. TANG Y, GILBERT DI, GLAUSER TA, HERSHEY AD, SHARP FR: Blood gene expression profiling of neurologic diseases: a pilot microarray study. Arch. Neurol. (2005) 62(2):210-215.
132. TOMSON T, BATTINO D, BONIZZONI E et al.: EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia (2004) 45(11):1463-1464.
133. MORROW J, RUSSEL A, GUTHRIE E et al.: Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatr. (2006) 77(2):193-198.